by Luke Timmerman in Microsoft , biotech , Seattle , Cancer , ICOS , Roundup , WIND , Solar , Biofuels , seattlepi , clean edge , dendreon , healthvault , Cell Therapeutics , National blog main , Seattle blog main , OncoGenex Pharmaceuticals , Calistoga Pharmaceuticals , David Cerino , CG Therapeutics , Denise Harrison , Cliff Stocks , Michael Gallatin , Albert Yu , Carol Gallagher

Biotech, Roundup, cancer Luke Timmerman wrote: Cancer drugs are one of the core strengths of Seattle’s life sciences hub, and this week we found a couple of intriguing stories about startups that haven’t been covered anywhere else in depth. —Seattle-based CG Therapeutics is moving ... [1 Citations]

Xconomy - Mar 12, 2009 - [ Feed - Focus - Exclude ]

by Luke Timmerman in biotech , Seattle , DRUGS , Cancer , Deals , ICOS , Life Sciences , Eli Lilly , inflammation , glaxosmithkline , novartis , Genentech , Cialis , National blog main , Seattle blog main , Alta Partners , Frazier Healthcare Ventures , CAL-101 , Three Arch Partners , Amgen Ventures , Oncothyreon , Calistoga Pharmaceuticals , Intellikine , Cliff Stocks , Michael Gallatin , Albert Yu , Carol Gallagher

Biotech, cancer, Inflammation Luke Timmerman wrote: Some members of the band that pumped out a one-hit wonder at Icos are getting back together to see if they can produce at least one more hit at Seattle-based Calistoga Pharmaceuticals. Calistoga has been building up its management team over the pas... [2 Citations]

Xconomy - Mar 11, 2009 - [ Feed - Focus - Exclude ]